The data of 72 cases of advanced schistosomiasis portal hypertension patients who received surgical treatment were retrospectively analyzed in the Fifth People's Hospital of Changde City from January, 1999 to January, 2011. Postoperative complications occurred in 17 cases, and the rate was 23.6%, including intra-abdominal bleeding in 2 cases, postoperative infection in 5 cases, recent upper gastrointestinal bleeding in 3 cases, massive ascites in 2 cases, persistent fever in 3 cases, and unusual increase of platelets and portal vein thrombosis in 2 cases.
Download full-text PDF |
Source |
---|
Stem Cell Res Ther
January 2025
Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, P. R. China.
Background: Asthma is a prevalent respiratory disease, and its management remains largely unsatisfactory. Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in reducing airway inflammation in experimental allergic diseases, representing a potential alternative treatment for asthma. Migrasomes are recently identified extracellular vesicles (EVs) generated in migrating cells and facilitate intercellular communication.
View Article and Find Full Text PDFJ Fluoresc
January 2025
Department of Chemical Sciences, University of Johannesburg, Doornfontein, Johannesburg, South Africa.
Point of Care (POC) diagnosis provides an effective approach for controlling and managing Neglected Tropical Diseases (NTDs). Electrochemical biosensors are well-suited for molecular diagnostics due to their high sensitivity, cost-effectiveness, and ease of integration into POC devices. Schistosomiasis is a prominent NTD highly prevalent in Africa, Asia, and Latin America, with significant socioeconomic implications such as discrimination, reduced work capacity, or mortality, perpetuating the cycle of poverty in affected regions worldwide.
View Article and Find Full Text PDFFront Parasitol
March 2024
Center for Research in Infectious Diseases, College of Graduate Studies and Research, Mount Kenya University, Thika, Kenya.
Introduction: Schistosomiasis (Bilharzia), a neglected tropical disease caused by parasites, afflicts over 240 million people globally, disproportionately impacting Sub-Saharan Africa. Current diagnostic tests, despite their utility, suffer from limitations like low sensitivity. Polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) remain the most common and sensitive nucleic acid amplification tests.
View Article and Find Full Text PDFEgypt J Immunol
January 2025
Department of Medical Parasitology, Faculty of Medicine (girls), Al-Azhar University, Cairo, Egypt.
Hepato-intestinal schistosomiasis is characterized by severe pathological changes at advanced chronic stages, including granulomatous lesions and liver fibrosis. The objective of our research was to assess the dynamic expression of profibrotic molecules, the transforming growth factor beta 1 (TGF-β1), and proinflammatory cytokines immunomodulation induced by interleukin 17 (IL-17) neutralization in murine Schistosomiasis mansoni. The study included 56 specific pathogen-free male C57BL/6 mice, divided into 3 main groups: GI uninfected normal controls, GII S.
View Article and Find Full Text PDFEur J Med Chem
February 2025
Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123, Allschwil, Switzerland; University of Basel, P.O. Box CH-4003, Basel, Switzerland. Electronic address:
For over three decades, praziquantel (PZQ) has been the mainstay chemotherapy for prevention and treatment of schistosomiasis. The excessive use of PZQ, coupled with the lack of advanced drug candidates in the current anti-schistosomiasis drug development pipeline, emphasizes the genuine need for new drugs. In the current work, we investigated the antischistosomal potential of a new series of compounds derived from the privileged benzimidazole scaffold, which exhibited low micromolar IC potency in the range of 1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!